Benitec BioPharma (BNTC) Reiterated at Market Outperform by Citizens After OPMD Data

February 25, 2026 5:10 AM EST Send to a Friend
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $22.00 price target on Benitec BioPharma (NASDAQ: BNTC).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login